Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

83 results
Display

Does the timing of cabergoline administration impact rates of ovarian hyperstimulation syndrome?

Rubenfeld ES, Dahan MH

Objective Does the timing of cabergoline administration impact the rate of mild/moderate ovarian hyperstimulation syndrome in women with a GnRH agonist trigger? Methods We conducted a retrospective cohort analysis of 285...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
An Update of Gonadotropin-Releasing Hormone Antagonists in the Treatment of Advanced Prostate Cancer

Hong JH

For decades, androgen deprivation therapy (ADT) was the cornerstone treatment for advanced prostate cancer. ADT using gonadotropin-releasing hormone (GnRH) agonist or antagonist acts by blocking the hypothalamic-pituitary-gonadal system with different...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The role of gonadotropin-releasing hormone agonists in female fertility preservation

Lee JH, Choi YS

Advances in anticancer treatments have resulted in increasing survival rates among cancer patients. Accordingly, the quality of life after treatment, particularly the preservation of fertility, has gradually emerged as an...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Changes in body mass index in boys with central precocious puberty over 2 years of gonadotropin-releasing hormone agonist therapy

Lim KI, Lee HS, Hwang JS

Purpose: Gonadotropin-releasing hormone agonist (GnRHa) is a safe and effective therapy used to treat central precocious puberty (CPP). Although most studies have reported no significant difference in body mass index...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Gonadotropin-releasing hormone stimulation test and diagnostic cutoff in precocious puberty: a mini review

Ab Rahim SN, Omar J, Tuan Ismail TS

The gonadotropin-releasing hormone (GnRH) stimulation test is a valuable tool in diagnosing and differentiating causes of early pubertal occurrences. Utility of the test can be limited in some instances, however,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Dizygotic twin sisters with normosmic idiopathic hypogonadotropic hypogonadism caused by an FGFR1 gene variant

Choe J, Kim JH, Kim YA, Lee J

Isolated hypogonadotropic hypogonadism (IHH) is a rare genetic disorder that is clinically and genetically heterogeneous. It is characterized by absent or incomplete pubertal development owing to an isolated defect in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Prevalence of idiopathic scoliosis in girls with central precocious puberty: effect of a gonadotropin-releasing hormone agonist

Chung LY, Nam HK, Rhie YJ, Huh R, Lee KH

Purpose: Adolescent idiopathic scoliosis (AIS) is the most common form of scoliosis and occurs in children between 10 to 18 years old, during periods of growth spurts and puberty changes....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effect of Timing of GonadotropinReleasing Hormone Agonist Administration for Ovarian Protection in Patients with Breast Cancer

Shin JJ, Choi YM, Jun JK, Lee KH, Kim TY, Han W, Im SA

Purpose: This study was performed to investigate the effect of the interval between the start of gonadotropin-releasing hormone agonist (GnRHa) and the start of chemotherapy on ovarian protection in patients...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Relationship between final adult height and birth weight after gonadotropin-releasing hormone agonist treatment in girls with central precocious puberty

Cho AY, Ko SY, Lee JH, Kim EY

Purpose: The clinical significance of birth weight relative to gestational age in girls with central precocious puberty is unclear. This study sought to compare clinical parameters such as final adult...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Change in Estradiol Levels among Premenopausal Patients with Breast Cancer Treated Using Leuprolide Acetate 11.25 Milligrams 3-Month Depot and Tamoxifen

Lee Yj, Wu ZY, Kim Hj, Lee JW, Chung IY, Kim J, Lee SB, Son BH, Kim SB, Jung JH, Gong G, Ahn SH, Ko B

The combination of luteinizing hormone-releasing hormone analogs (LHRHa) with tamoxifen is used as a standard postoperative adjuvant therapy in patients with hormone receptor-positive/premenopausal breast cancer. Long-acting LHRHa formulations offer advantages...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Association of maxillary dental developmental abnormality with precocious puberty: a case-control study

Kim Y, Lee NK, Kim JH, Ku JK, Lee BK, Jung HI, Choi SK

Background Dental studies of precocious puberty have focused on examination of jaw and dentition growth. The aim of the study was to analyze the relationship between precocious puberty and maxillary dental...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A pilot study of gonadotropin-releasing hormone agonist combined with aromatase inhibitor as fertility-sparing treatment in obese patients with endometrial cancer

Zhang Z, Huang H, Feng F, Wang J, Cheng N

OBJECTIVE: This study aims to evaluate the effects and pregnancy outcomes of gonadotropin-releasing hormone agonist (GnRH agonist) combined with aromatase inhibitor (AI) in preserving the fertility of obese women with...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparing adult height gain and menarcheal age between girls with central precocious puberty treated with gonadotropin-releasing hormone agonist alone and those treated with combined growth hormone therapy

Kim MS, Koh HJ, Lee GY, Kang DH, Kim SY

PURPOSE: This study aimed to investigate the outcomes of gonadotropin-releasing hormone agonist (GnRHa) therapy with or without growth hormone (GH) therapy for girls with idiopathic central precocious puberty (CPP). METHODS: The...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Morning basal luteinizing hormone, a good screening tool for diagnosing central precocious puberty

Lee DM, Chung IH

PURPOSE: The standard method used to diagnose central precocious puberty (CPP) is the gonadotropin releasing hormone stimulation test (GnRHST). However, this test is inconvenient for children because it is time-consuming...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Posterior reversible encephalopathy syndrome in a woman who used gonadotropin-releasing hormone agonists: a case report

Lee M, Kim TH, Kim SJ, Jee BC

Posterior reversible encephalopathy syndrome (PRES) is a newly described adverse effect possibly associated with gonadotropin-releasing hormone (GnRH) agonist therapy. We report a case of PRES after 2 doses of depot...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Early gonadotropin-releasing hormone antagonist protocol in women with polycystic ovary syndrome: A preliminary randomized trial

Shin JJ, Park KE, Choi YM, Kim HO, Choi DH, Lee WS, Cho JH

OBJECTIVE: To prospectively evaluate the efficacy and safety of a fixed early gonadotropin-releasing hormone (GnRH) antagonist protocol compared to a conventional midfollicular GnRH antagonist protocol and a long GnRH agonist...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison of the clinical outcome of frozen-thawed embryo transfer with and without pretreatment with a gonadotropin-releasing hormone agonist

Kang J, Park J, Chung D, Lee SH, Park EY, Han KH, Choi SJ, Chung IB, Han HD, Jung YS

OBJECTIVE: To describe the clinical outcomes of frozen-thawed embryo transfer (FET) with artificial preparation of the endometrium, using a combination of estrogen (E2) and progesterone (P4) with or without a...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Gonadotropin-releasing Hormone Agonist Plus Aromatase Inhibitor in the Treatment of Uterine Leiomyoma in Near Menopause Patient: A Case Series Study

Moradan S

OBJECTIVES: There are many drugs for of symptomatic fibroids. Gonadotropin-releasing hormone (GnRH) agonists are the well known drugs. Also, aromatase inhibitors are effective. All published studies surveyed the effect of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Longitudinal follow-up to near final height of auxological changes in girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analog and grouped by pretreatment body mass index level

Park J, Hwang TH, Kim YD, Han HS

PURPOSE: Reported changes in body mass index (BMI) in central precocious puberty (CPP) during and after gonadotropin-releasing hormone analog (GnRHa) treatment are inconsistent. We, therefore, investigated auxological parameters in GnRHa-treated...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy of Combined Aromatase Inhibitor and Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Metastatic Breast Cancer

Kim SH, Choi J, Park CS, Kim HA, Noh WC, Seong MK

PURPOSE: Endocrine therapy is the preferred treatment for hormone receptor (HR)-positive metastatic breast cancer (MBC). We investigated the efficacy of combined aromatase inhibitor (AI) and luteinizing hormone-releasing hormone (LHRH) agonist...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr